www.perlentaucher.de/autor/joachi...
#Sartorius ist auch als Lyriker und Übersetzer hervorgetreten. Er ist Herausgeber der Gesammelten Werke von Malcolm Lowry und William Carlos Williams

Joachim Sartorius – Wikipedia

de.wikipedia.org/wiki/Joachim...
Joachim #Sartorius (* 19. März 1946 in Fürth) ist ein deutscher Lyriker, Jurist, Diplomat, Festspielintendant und Übersetzer.
1974-1986 im deutschen diplomatischen Dienst tätig: Zuerst als Kulturreferent in New York, anschließend als Pressereferent in Ankara,

Sartorius Aktie: Wachstumskurs bestätigt Sartorius bestätigt mit dem Geschäftsbericht 2025 eine deutliche Umsatz- und Margensteigerung. Für das laufende Jahr peilt der Konzern eine operative...

#Sartorius bestätigt mit dem #Geschäftsbericht 2025 eine deutliche Umsatz- und Margensteigerung. Für das laufende Jahr peilt der Konzern eine operative EBITDA-Marge von über 30 Prozent an.

www.boerse-express.com/news/article...

Kissigs Nebenwerte-Analyse zu Sartorius: Bringt der neue Chef auch die Aktie wieder in die Erfolgsspur? Börsenblog zum Thema Value Investing, dem langfristigen Investieren in unterbewertete und ertragsstarke Aktien.

#Sartorius und der MedTech-Sektor hatten drei Jahre lang schwer zu kämpfen und auch Anleger haben ordentlich Federn gelassen. Operativ dreht sich der Wind und der neue Chef könnte Sartorius wieder zurück in die Erfolgsspur bringen - auch die Aktie?!
www.intelligent-investieren.net/2025/10/kiss...

Sartorius Vz. Aktie: Kursrallye Richtung 300 Euro möglich? Ausbruch gelungen? Die Sartorius Vz. Aktie ist mit einem Kursplus von fast 10 Prozent gestern über die 200-Tage-Linie geklettert. Aktuell werden auf Tradegate 218,20 Euro für den TecDAX-Titel

Sartorius Vz. Aktie: Kursrallye Richtung 300 Euro möglich? ... www.4investors.de/nachrichten/... #sartorius #aktien #4investors

Sartorius Vz. Aktie: Das könnte sehr gefährlich werden... Die Sartorius Vz. Aktie hat sich zuletzt zwar erholt, doch der Kurs des DAX-Titels scheiterte in den letzten Tagen mehrfach an einem entscheidenden Widerstandsbereich um 200 Euro. Am gestrigen

Sartorius Vz. Aktie: Das könnte sehr gefährlich werden... ... www.4investors.de/nachrichten/... #sartorius #aktien #4investors

🤑DAX höher: E.on, #Renk, #Brenntag, #Porsche, #Cisco mit Zahlen, #Sartorius, #SAP, #Rheinmetall im Fokus

Willkommen, Ihre Kommentare zu hinterlassen und Ideen auszutauschen! Liken und folgen Sie, um mehr über die neuesten Investitionstrends und -empfehlungen zu erfahren! 👍 #Aktien #Finanzen

💢DAX höher: E.on, #Renk, #Brenntag, #Porsche, #Cisco mit Zahlen, #Sartorius, #SAP, #Rheinmetall im Fokus

Willkommen, Ihre Kommentare zu hinterlassen und Ideen auszutauschen! Liken und folgen Sie, um mehr über die neuesten Investitionstrends und -empfehlungen zu erfahren! 👍 #Aktien #Finanzen

Sartorius Vz. Aktie: Zwischen Comeback-Chance und Baisse-Risiko Die Sartorius Vz. Aktie hat nach einer mehrwöchigen Schwächephase gestern ein kräftiges Lebenszeichen gesendet. Am Dienstag legte der DAX-Wert auf XETRA um mehr als 7 Prozent zu und schloss bei

Sartorius Vz. Aktie: Zwischen Comeback-Chance und Baisse-Risiko ... www.4investors.de/nachrichten/... #sartorius #aktien #4investors

Jefferies starts Sartorius ordinaries at Buy, upgrades preferred shares Investing.com -- Jefferies has initiated coverage on Sartorius ordinary shares (ords) with a Buy rating and a €210 price target, while upgrading the preference shares (prefs) to Buy from Hold and raising the target to €263. The bank maintained its Buy on Sartorius Stedim (EPA:STDM) Biotech (VIE:DIM) but cut the price target to €229 from €245. The new coverage on Sartorius reflects the bank’s view that the market could increasingly focus on the relative value between the ords and prefs, especially ahead of a potential shift in the shareholder structure in 2028. The current float of SRT ords is about 7%, with the majority held in the “Horst Sartorius Community of Heirs,” which will dissolve in July 2028. “Logically we would expect the market to focus more on the discount of the Ords to the Prefs (currently -18%),” analyst James Vane-Tempest said in a note. The preference shares carry no voting rights but offer a one-cent higher dividend per share and are significantly more liquid, with average daily turnover of about $32.8 million compared to $1.4 million for the ordinaries. Jefferies applies a 20% discount to the ordinaries versus the preference shares in its valuation. The broker’s analysis also points to potential changes in Bio-Rad’s stake in SRT, currently at 37.9%, which could rise to 40.2% if a 2021 loan to a holding company controlled by one of the heirs is settled in shares when the trust dissolves. Jefferies’ forecasts imply that the market is pricing in below-market growth for both prefs and Sartorius Stedim Biotech shares, despite company guidance for low-teens annual sales growth through 2028. The firm’s price targets for the two correspond to full-year 2026 EV/EBITDA multiples of 22.2x and 23.7x, respectively. Before you buy stock in STDM, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is STDM one of them?

Click Subscribe #Investing #Stocks #MarketNews #Sartorius #Jefferies

Sartorius reports 6.1% sales growth, confirms 2025 guidance Investing.com -- Sartorius AG (ETR:SATG) (ETR:SRT) reported a 6.1% increase in group sales revenue for the first six months of 2025, according to financial results released Tuesday. The company’s underlying EBITDA showed significant improvement, rising by 11.9% to €527 million in the first half of the year. Underlying net profit demonstrated even stronger growth, increasing by 13.7% to €169 million compared to €148 million in the same period of 2024. Sartorius confirmed its guidance for 2025, though the company noted that its sales revenue and margin forecast does not include possible effects of tariffs or related mitigating and corrective measures. Management expressed confidence in the company’s market position, stating they do not expect any influence on Sartorius’s strong market position and competitiveness. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if SATG is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #Sartorius #SalesGrowth #FinancialResults #Investing #EBITDA

Sartorius Stedim Biotech reports 9.4% sales growth in first half Investing.com -- Sartorius Stedim (EPA:STDM) Biotech SA (DIM) on Tuesday reported sales revenue of €1,490 million for the first half of 2025, representing a 9.4% increase compared to the same period last year. The company’s underlying EBITDA rose by 19.3% to €462 million in the first six months of the year, showing stronger profit growth than revenue expansion. Net profit for the half-year period reached €154.1 million, according to the company’s financial report released Tuesday. Management has confirmed its guidance for the full year 2025, maintaining its previously announced financial targets, though specific details of the outlook were not provided in the results announcement. Sartorius Stedim Biotech, which specializes in biopharmaceutical manufacturing equipment and services, continues to show growth despite challenging market conditions in the bioprocessing sector. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks AI – 6 model portfolios fueled by AI stock picks with a stellar performance this year... In 2024 alone, ProPicks AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if STDM is on your watchlist, it could be very wise to know whether or not it made the ProPicks AI lists.

Click Subscribe #Sartorius #Biotech #SalesGrowth #Investing #FinancialReport

Yugioh GX cosplay of...well.. myself. "The light sought to restore justice and peace". #Cosplay #yugioh #sartorius #gaming #YGOGX #yugiohGX #cosplayer #saiou #GodFirst

Lo que nos jugamos Claro que el asunto Cerdán, Ábalos, Koldo puede ser aberrante y exige que se tomen medidas rápidas y contundentes. Pero, ¿por qué creen ustedes que existe ese ansia, avidez o impaciencia por acabar co...

El articulo de #Sartorius debería ser leído y difundido por doquier para entender lo que nos jugamos los españoles siguiendo mensajes de quienes prefieren que España se hunda.
👇
www.eldiario.es/opinion/trib...

The Sartorius PI Forum in Boston: A Turning Point for Biomanufacturing Innovations Discover how the Sartorius PI Forum is paving the way for advancements in biomanufacturing, focusing on sustainability and efficiency in drug production.

The Sartorius PI Forum in Boston: A Turning Point for Biomanufacturing Innovations #United_States #Boston #Sartorius #Biomanufacturing #PI_Forum

Sartorius Hipersep Flowdrive Pilot Preparative HPLC Chromatography System | eBay New Sartorius Hipersep Flowdrive Pilot Preparative HPLC Chromatography System, serial number 3998-H, built 2022.

🌟 FOR SALE: New 2022 #Sartorius Hipersep Flowdrive Pilot #HPLC System!
Advanced, reliable #chromatography technology for #labs. Unmatched efficiency awaits—seize this rare opportunity
📞 Act now ✉️!
www.ebay.com/itm/36556880...

Click Subscribe #Sartorius #StockMarket #Profit #Investing #Finance

VectorBuilder and Sartorius Forge Alliance for Biopharmaceutical Advancement VectorBuilder and Sartorius have entered a strategic partnership focused on enhancing biopharmaceutical innovation through advanced gene delivery solutions and mRNA development.

VectorBuilder and Sartorius Forge Alliance for Biopharmaceutical Advancement #VectorBuilder #Sartorius #Biopharmaceutical

VectorBuilder and Sartorius Collaborate for Biopharmaceutical Innovation and Development VectorBuilder and Sartorius have entered a strategic partnership focused on innovative biopharmaceutical projects, enhancing gene delivery and mRNA technologies.

VectorBuilder and Sartorius Collaborate for Biopharmaceutical Innovation and Development #China #Guangzhou #VectorBuilder #Sartorius #Biopharma

SUSS MicroTec #Sartorius - der eine gefeiert, der andere gefeuert. Prognoseänderungen mit extremer Kurswirkung. Handlungsbedarf? #sdax #börse #aktien #stockstobuy #stockstosell #tradingview #invest #stocks #semiconductor #dortmund #investment
www.nebenwerte-magazin.com/?p=33635

Delighted to announce that we not only successfully published a project together with #Sartorius assessing the activity of extractables from single-use applications in the #CellPainting assay, but this is also the first joint paper of my wife and me.
doi.org/10.1038/s415...